Cargando…

Overactive IGF1/Insulin Receptors and NRASQ61R Mutation Drive Mechanisms of Resistance to Pazopanib and Define Rational Combination Strategies to Treat Synovial Sarcoma

Pazopanib is approved for treatment of advanced soft tissue sarcomas, but primary and secondary drug resistance limits its clinical utility. We investigated the molecular mechanisms mediating pazopanib resistance in human synovial sarcoma (SS) models. We found reduced cell sensitivity to pazopanib a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lanzi, Cinzia, Dal Bo, Laura, Favini, Enrica, Tortoreto, Monica, Beretta, Giovanni Luca, Arrighetti, Noemi, Zaffaroni, Nadia, Cassinelli, Giuliana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468361/ https://www.ncbi.nlm.nih.gov/pubmed/30909453 http://dx.doi.org/10.3390/cancers11030408

Ejemplares similares

Upregulation of ERK-EGR1-heparanase axis by HDAC inhibitors provides targets for rational therapeutic intervention in synovial sarcoma
por: Lanzi, Cinzia, et al.
Publicado: (2021)

Antitumor efficacy of the heparan sulfate mimic roneparstat (SST0001) against sarcoma models involves multi-target inhibition of receptor tyrosine kinases
por: Cassinelli, Giuliana, et al.
Publicado: (2016)

Interferon alpha-inducible protein 6 regulates NRASQ61K-induced melanomagenesis and growth
por: Gupta, Romi, et al.
Publicado: (2016)

Antitumour and antiangiogenic effects of IDN 5390, a novel C-seco taxane, in a paclitaxel-resistant human ovarian tumour xenograft
por: Petrangolini, G, et al.
Publicado: (2004)

Heparan Sulfate Mimetics in Cancer Therapy: The Challenge to Define Structural Determinants and the Relevance of Targets for Optimal Activity
por: Lanzi, Cinzia, et al.
Publicado: (2018)

PLK1 is a critical determinant of tumor cell sensitivity to CPT11 and its inhibition enhances the drug antitumor efficacy in squamous cell carcinoma models sensitive and resistant to camptothecins
por: Zuco, Valentina, et al.
Publicado: (2015)

Beyond targeting amplified MDM2 and CDK4 in well differentiated and dedifferentiated liposarcomas: From promise and clinical applications towards identification of progression drivers
por: Cassinelli, Giuliana, et al.
Publicado: (2022)

Editorial: Heparan Sulfate Proteoglycans and Their Endogenous Modifying Enzymes: Cancer Players, Biomarkers and Therapeutic Targets
por: Lanzi, Cinzia, et al.
Publicado: (2020)

Pre-clinical and clinical significance of heparanase in Ewing’s sarcoma
por: Shafat, Itay, et al.
Publicado: (2011)

Proteomic approach toward determining the molecular background of pazopanib resistance in synovial sarcoma
por: Qiao, Zhiwei, et al.
Publicado: (2017)

Targeting of RET oncogene by naphthalene diimide-mediated gene promoter G-quadruplex stabilization exerts anti-tumor activity in oncogene-addicted human medullary thyroid cancer
por: Lopergolo, Alessia, et al.
Publicado: (2016)

miRNAs as Therapeutic Tools and Biomarkers for Prostate Cancer
por: Arrighetti, Noemi, et al.
Publicado: (2021)

Activation of ERK1/2 Causes Pazopanib Resistance via Downregulation of DUSP6 in Synovial Sarcoma Cells
por: Yokoyama, Nobuhiko, et al.
Publicado: (2017)

Effects of Pazopanib Monotherapy vs. Pazopanib and Topotecan Combination on Anaplastic Thyroid Cancer Cells
por: Di Desidero, Teresa, et al.
Publicado: (2019)

Pazopanib and anti-VEGF therapy
por: Drabkin, Harry A
Publicado: (2010)

Pazopanib and Statin-Induced Rhabdomyolysis
por: Logue, Jennifer M., et al.
Publicado: (2017)

Phototoxic Reaction Induced by Pazopanib
por: Udompanich, Siriorn, et al.
Publicado: (2018)

Tension Pneumothorax: Is it Sarcoma or Pazopanib?
por: Sebanayagam, Vinoja, et al.
Publicado: (2020)

Pazolimus: pazopanib plus sirolimus following progression on pazopanib, a retrospective case series analysis
por: Katz, D., et al.
Publicado: (2016)

IGF-1 Regulates Cyr61 Induced Breast Cancer Cell Proliferation and Invasion
por: Sarkissyan, Suren, et al.
Publicado: (2014)

PMON61 Evaluation of elevated IGF-1 in patients without clinical evidence of acromegaly
por: Careless, Laura, et al.
Publicado: (2022)

Pazopanib: Approval for Soft-Tissue Sarcoma
por: Nguyen, Diana T., et al.
Publicado: (2013)

Pazopanib for the treatment of soft-tissue sarcoma
por: Heudel, Pierre, et al.
Publicado: (2012)

Pazopanib induced hand-foot syndrome
por: Sundriyal, Deepak, et al.
Publicado: (2015)

Pazopanib-Induced Alopecia, an Underestimated Toxicity?
por: Biondo, Andrea, et al.
Publicado: (2015)

Pazopanib-Induced Severe Acute Pancreatitis
por: Kawakubo, Kazumichi, et al.
Publicado: (2015)

Thrombotic Thrombocytopenic Purpura Associated with Pazopanib
por: Syed, Umer, et al.
Publicado: (2018)

Pazopanib in advanced soft tissue sarcomas
por: Lee, Alex T. J., et al.
Publicado: (2019)

Kir6.1- and SUR2-dependent K(ATP) overactivity disrupts intestinal motility in murine models of Cantú syndrome
por: York, Nathaniel W., et al.
Publicado: (2020)

The Botulinum Treatment of Neurogenic Detrusor Overactivity: The Double-Face of the Neurotoxin
por: Traini, Chiara, et al.
Publicado: (2019)

Relative Dose Intensity of Induction-Phase Pazopanib Treatment of Soft Tissue Sarcoma: Its Relationship with Prognoses of Pazopanib Responders
por: Nakano, Kenji, et al.
Publicado: (2019)

The impact of a 1‐hour time interval between pazopanib and subsequent intake of gastric acid suppressants on pazopanib exposure
por: Krens, Stefanie D., et al.
Publicado: (2021)

miR-199a-3p displays tumor suppressor functions in papillary thyroid carcinoma
por: Minna, Emanuela, et al.
Publicado: (2014)

Posterior Reversible Leukoencephalopathy Syndrome Associated with Pazopanib
por: Foerster, Robert, et al.
Publicado: (2013)

Reversible Posterior Leukoencephalopathy Syndrome Induced by Pazopanib
por: Chelis, Leonidas, et al.
Publicado: (2012)

Pazopanib and pancreatic toxicity: a case report
por: Russano, Marco, et al.
Publicado: (2015)

Pazopanib radio-sensitization of human sarcoma tumors
por: Wang, Feng, et al.
Publicado: (2018)

Pazopanib-induced Endothelial Injury with Podocyte Changes
por: Maruyama, Keisuke, et al.
Publicado: (2017)

Rapid hair depigmentation in patient treated with pazopanib
por: Šeparović, Robert, et al.
Publicado: (2018)

The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by Neratinib
por: Booth, Laurence, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5jltbssgumtk3fpfoic1uh0j3l